Bain research shows Covid-19 is likely to prompt long-term shifts in patient behavior, hospital workflows, pharma sales models and supply-chain tracking. The pandemic already has sharply increased the number of first-time users of telehealth and accelerated the growth of online pharmacy channels. Hospitals are implementing new triage methods for diagnosis and treatment and seeking to ensure local sources for vital items to back up the existing supply chain.
As the healthcare landscape evolves, pharma companies plan to change their go-to-market models and reconfigure supply chains to improve product tracking. To adapt to the speed and breadth of change, leaders are increasing investment in digital capabilities. As the healthcare industry evolves, healthcare profit pools will shift, creating new winners and losers.
Implications for Healthcare Private Equity Investors in Europe
Leaders with Bain's Private Equity and Healthcare practices explain how the Covid-19 pandemic is affecting European private equity investors in the healthcare sector and what companies are doing to recover
The global Covid-19 pandemic has extracted a terrible human toll and spurred sweeping changes in the world economy. Across industries, executives have begun reassessing their strategies and repositioning their companies to thrive now and in the world beyond coronavirus.